Metraipolis › archive › dc_602adfe4601c
Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42389543
- DOI
- 10.3389/fimmu.2026.1793368
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T08:59:04.851Z
- SHA-256 of the archived text
5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7- Stable URL of this page
https://metraipolis.com/documento/dc_602adfe4601c
How to cite
Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543 — Europe PMC (en), https://europepmc.org/article/MED/42389543 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_602adfe4601c (Metraipolis archive dc_602adfe4601c, sha256 5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7)
BibTeX
@misc{dc602adfe4601c,
title = {Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42389543},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_602adfe4601c; sha256 5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42389543. Agents can read the archived copy with the MCP tool read_document.